EP0977880A2 - Produits agissant contre des affections retiniennes et traitement correspondant - Google Patents

Produits agissant contre des affections retiniennes et traitement correspondant

Info

Publication number
EP0977880A2
EP0977880A2 EP98922042A EP98922042A EP0977880A2 EP 0977880 A2 EP0977880 A2 EP 0977880A2 EP 98922042 A EP98922042 A EP 98922042A EP 98922042 A EP98922042 A EP 98922042A EP 0977880 A2 EP0977880 A2 EP 0977880A2
Authority
EP
European Patent Office
Prior art keywords
promoter
cells
construct
raav
retinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98922042A
Other languages
German (de)
English (en)
Inventor
William W. Hauswirth
John G. Flannery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida filed Critical University of Florida
Publication of EP0977880A2 publication Critical patent/EP0977880A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Definitions

  • the subject invention was made with government support under a research project supported by NIH Grant Nos. EY07864 and EY11123 .
  • the government has certain ⁇ ghts m this invention.
  • Retmitis pigmentosa is a collection of he ⁇ table retinal degenerations caused by defects in one of several genes for proteins of photoreceptor (PR) cells.
  • PR photoreceptor
  • RP is a clinically and genetically heterogeneous group of conditions characte ⁇ zed by progressive rod photoreceptor degeneration and eventual blindness.
  • All are either directly or indirectly involved in the rod cell specific visual response.
  • the exact molecular pathogenesis of RP is still unexplained. Ultrastructural observations suggest that the rod PRs are severely affected m the disease.
  • RP families have been documented with dominant, recessive, X-linked, and digemc patterns of inheritance, and more than fifteen separate loci have been implicated by linkage studies. Currently, the mutations identified to date all occur in genes exhibiting a PR-specific pattern of expression. Approximately 50,000 individuals m the United States are estimated to have RP.
  • Macular degeneration is a detenoration of the macula (the cone-rich center of vision) leading to gradual loss of central vision. Eventual loss of these cones leads to central vision loss and functional blindness. Macular degeneration may also have a genetic etiology or predisposition. Although a genetic etiology has not yet been established, based on pedigree studies it is very likely to exist. At least 500,000 individuals are estimated to suffer from macular degeneration currently in the United States.
  • the subject invention concerns materials and methods for achieving expression of proteins in retina cells.
  • the expression of proteins in retina cells can be used, for example, for the treatment of retinal diseases. More specifically, the subject invention provides polynucleotide sequences, and methods for using these sequences, to achieve highly specific expression of proteins in the retma. As described herein, the expression of these proteins can be used to treat a variety of retinal diseases.
  • the mate ⁇ als and methods of the subject invention can be used to treat autosomal dominant retmitis pigmentosa (ADRP).
  • ADRP autosomal dominant retmitis pigmentosa
  • the subject invention provides techniques for obtaining targeted, high level expression of any desired gene in the photoreceptor cells of the retina.
  • Rods and cones are the pnncipal cell types affected in retmitis pigmentosa and macular degeneration respectively, hence the ability to target expression of therapeutic genes to these cells without altering unaffected cell types m the retma provides a genetic therapy approach of high specificity and low risk.
  • ribozymes can be highly and specifically expressed in the retina.
  • the ribozymes cleave the mutant forms of messenger RNA (mRNA) occurring in common forms of inherited retinal degeneration. This specificity makes these ⁇ bozymes able to destroy harmful mRNA while leaving normal mRNA mtact.
  • Ribozymes against other genetic forms of retmitis pigmentosa can be produced and used according to the subject invention.
  • Other polynucleotides encoding therapeutically useful products can also be selectively expressed in the eye using the teachings of the subject invention.
  • Figures la and lb show the construction of plasmids used according to the subject invention. These figures show a schematic diagram of the plasmid DNA constructs used to make rAAV viruses mOp-/ cZ (a) and Op-gfp (b).
  • TR 145 bp AAV terminal repeat sequence, mOp, 472 bp mu ⁇ ne rod opsm regulatory sequence from +86 to -388, SD/SA, 180 bp SV40 late viral protein gene 16S/19S splice donor and acceptor signal, lacZ; coding sequence for the bacterial lacZ gene; gfp, coding sequence for the synthetic green fluorescence gene; pA, pAl and pA2, polyadenylation signals; Epo, a tandem repeat of the polyoma virus enhancer region (bases 5210-5274); Ptk, thymidme kinase promoter of herpesvirus (bases 92-218); neo r , coding sequence of the neomycm resistance gene, Tn5 (bases 1555-2347) (Zolotukhin, S., M. Potter, W. Hauswirth, J. Guy, N. Muzyczka (1996) J. Virol. 70:4646-4654).
  • Figures 2a-2b show outer retinal layer with P23H ribozymes.
  • 2a measurements of ONL thickness (left), RIS length (middle), and ROS length ( ⁇ ght) m rats killed at different ages. Filled squares denote normal, non-transgemc animals.
  • P23H-3 rats were either unmjected (open squares), injected subretmally with PBS (open diamonds), or injected with AAV vectors carrying one of five ⁇ bozymes or controls.
  • Ribozymes were: Hpl 1 hairpm ⁇ bozyme (filled circles), Hhl3 hammerhead ⁇ bozyme (filled triangles), Hpl "inactive” hairpin ⁇ bozyme (open circles), Hhl3 ⁇ "inactive” hammerhead ⁇ bozyme (open t ⁇ angle), or BOPS-g/p (X), all regulated by the same bovine opsm promoter. All injections were performed at P 14-15. The error bars were omitted if they fell withm the symbol, except for Hpl li at P75 and P90, where only one eye at each point was examined.
  • Rats Measurements of ONL thickness along the vertical me ⁇ dian of the eye from the optic nerve head (ONH) to the ora serrata (anterior margin of the retma) in rats at P90. Rats were either unmjected (open triangles) or injected at P14-15 with Hpl 1 hairpm ribozymes (filled circles) or Hhl3 hammerhead ribozymes (open circles).
  • the subject invention pertains to materials and methods for achieving highly specific expression of desired proteins in the retina. These proteins can be used as described herein to achieve a beneficial therapeutic affect.
  • the subject invention provides materials and methods which can be used to reduce or eliminate the symptoms of mhe ⁇ ted eye disease caused by mutations in genes for retinal proteins.
  • the subject invention provides materials and methods for achieving efficient and cell type-specific expression of exogenous genes in photoreceptor cells (PRs) of the mammalian retina.
  • PRs photoreceptor cells
  • rAAV recombmant Adeno-associated Virus
  • the subject invention provides a method for treating autosomal dominant retmitis pigmentosa (ADRP) at a molecular level.
  • ADRP autosomal dominant retmitis pigmentosa
  • Gene therapy for ADRP involves (1) an efficient and cell-type specific gene delivery/expression system, and (2) a selective means of inhibiting production of the mutant protein.
  • rAAV vectors are used to transfer the bacte ⁇ al lac gene or a synthetic green fluorescent protein gene (gfp) to mouse or rat retinas following injection into the subretmal space.
  • gfp synthetic green fluorescent protein gene
  • results demonstrate the surprising and advantageous ability to achieve highly specific expression of proteins m the mammalian retma.
  • reporter gene product was found exclusively in photoreceptors, not in any other retinal cell type or in the adjacent retinal pigment epithelium (RPE).
  • GFP-expressmg photoreceptors typically encompassed 10-20% of the total retinal area following a single 2 ⁇ injection. Both rod and cone photoreceptors were transduced with nearly 100% efficiency in the region directly surrounding the injection site. Approximately 2.5 million photoreceptors were transduced as a result of the single subretmal inoculation. The use of such proximal opsm promoters therefore can be used to substantially enhance the efficiency of expression in cases where rod and/or cone -specific expression of a potentially therapeutic gene is desired.
  • the gfp- contaimng rAAV stock was substantially free of both adenovirus and wild-type AAV, as judged by plaque assay and infectious center assay, respectively.
  • helper virus- free rAAV vectors can achieve high frequency tissue-specific transduction of terminally differentiated, postmitotic photoreceptor cells.
  • the human rod opsm, or cone opsm, promoter analogous to the mouse sequence would be used.
  • the appropriate regions of the human sequence can be readily identified and used by the skilled artisan having the benefit of the instant disclosure Assuming a 20 ⁇ l injection into the central human retma at the region of greatest rod density, approximately 8 million rods would be expected to be transduced m a focal region encompassing approximately 6% of the total retina. By transducing such an area of PRs it is possible to improve or delay retinal degenerations in a variety of mhe ⁇ ted retinal diseases.
  • PR genes of therapeutic potential have been identified experimentally by virtue of their involvement in recessive human retinal disease and by their ability at least to delay the course of recessive RP- ke disease animal models.
  • PDE-B Bossham, J., T. Tanabe, D. Sun, Y. Zeng, H. Kjeldbye, P. Gouras, A.M. Maguire (1996) Nature Med. 2:649-654; Lem, J., J. Flannery, T. Li, M. Applebury, D. Forber, M. Simon (1992) Proc. Natl Acad. Sci. USA 89:4422-4426
  • pe ⁇ phe ⁇ n/rds Travis, G.H., K.R. Groshan, M.
  • Brain Sci. 18:452-467 descnbed to date are potential candidates for therapy m this context.
  • the subject invention utilizes the catalytic properties of ⁇ bozymes.
  • Ribozymes are enzymes comp ⁇ sed of ⁇ bonucleic acid (RNA). In nature, ⁇ bozymes conduct a va ⁇ ety of reactions involving RNA, including cleavage and hgation of polynucleotide strands.
  • the specificity of ⁇ bozymes is determined by base pai ⁇ ng (hydrogen bonding) between the targeting domain of the ⁇ bozyme and the substrate RNA. This specificity can be modified by alte ⁇ ng the nucleotide sequence of the targeting domain.
  • ⁇ bozymes are continuously produced in the retinal cells from a copy of the ⁇ bozyme integrated m the patient's DNA.
  • patients require a single mtra-ocular injection and do not require hospitahzation. Long term (more than 15 months) unattenuated expression of proteins has been observed in cells transformed as described herein.
  • the subject invention concerns synthetic genes for several ribozymes.
  • ribozymes can recognize, for example, the nucleotide change causing the P23H mutation in one form of ADRP and the S334ter mutation in another.
  • Genes can be constructed which encode ⁇ bozymes having the ability to specifically destroy target RNA's for mutant retina proteins. With the benefit of the teachings provided herein, the skilled artisan can construct genes encoding ribozymes which destroy mutant RNA molecules associated with human RP or other genetic retinal diseases.
  • rAAV recombmant Adeno-associated virus
  • the cone opsm promoter can also be used to d ⁇ ve expression selectively m photoreceptor cells.
  • the delivery-expression materials and methods of the subject invention can be used to replace any gene responsible for photoreceptor disease. Specific examples include the genes responsible for retmitis pigmentosa or macular degeneration. General survival-promoting genes such as growth factor and neurotrophm genes are also candidates for both recessive and dominant forms of retinal disease.
  • genes for agents such as ⁇ bozymes or t ⁇ plex-forming o gonucleotides that can be designed to eliminate specific genetic defects are candidates for treating retinal disease using this technique.
  • Assays for activity include morphological analysis of retinal degeneration, quantitative mRNA studies, and electroretmography.
  • the mOp-/ ⁇ cZ -rAAV plasmid DNA was made by first inserting the 4.3 kbp Bgl II/Bam HI fragment containing the proximal mu ⁇ ne rod opsm promoter (+86 to -385) and the entire lacZ gene of clone pRG3 (Lem, J., M. Applebury, J. Falk, J. Flannery, M. Simon (1991) J Biol Chem. 266:9667-9672) into the Bgl II sites of pTR which contains the AAV TR sequences and a SV40 polyadenylation sequence (Fig. la).
  • the mOp-gfp- rAAV plasmid DNA was made by first adding Not I linkers to the 472bp Bgl II/Xho I proximal opsm promoter fragment of pRG3 and inserting it into the Not I sites of pTRUF2 (Zolotukhin, S. M. Potter, W. Hauswirth, J. Guy, N. Muzyczka (1996) J Virol. 70:4646-4654) (Fig. lb) rAAV virus production and analysis.
  • human 293 cells were co-transfected with mOp-/ ⁇ cZ-rAAV or mOp-g/ >-rAAV plasmid DNA and the helper pIM45 plasmid DNA carrying the wtAAV genome without terminal repeats (Zolotukhm, S. M Potter, W. Hauswirth, J. Guy, N. Muzyczka (1996) J. Virol.
  • Injections (1 ⁇ l m mice and 2 ⁇ l m rats) were made into the right eye with blunt 32 gauge needle through an opening m the pars-plana, dehve ⁇ ng the rAAV suspension into the supe ⁇ or subretmal space. Control injections were made in the contralateral eye with PBS only. Injections were performed with an operating microscope and the subretmal location of the injected volume was confirmed by ophthalmoscopy.
  • Tissue analysis Animals were euthanized by intramuscular injection of ketamme, followed by phenobarbital overdose. The eyes were immediately enucleated and the site of virus injection marked. The cornea, lens and vitreous of each eye were removed and the poste ⁇ or eyecup placed m primary fixative.
  • eyecups were fixed in 0.5% glutaraldehyde in 0.1M Cacodylate buffer pH 7.5 for 15 mm. At room temperature. Following a 10 mm. Wash in PBS, the eyecups were incubated in an iron-based X-gel staining solution (Sanes, J., J. Rubenstem, J. Nicolas (1986) EMBO J. 5:3133-3142) in a shaking water bath at 35°C for 12 hours. For agarose embedment, retinas were detached from the RPE, submerged without dehydration in molten 5% agarose and cooled to 25 °C.
  • Retinas were sectioned in the transverse axis m lsotomc PBS on a vibratome at 50-100 ⁇ m. B ⁇ ght field and phase-contrast micrographs of whole mounts and ⁇ -galactosidase-stamed sections were made with a Zeiss Axiophot. GFP fluorescence was examined m retinal whole mounts and agarose embedded sections. Tissue fixation was minimized to reduce retinal autofluorescence. Retinas were detached from eyecups, fixed for 15 mm. At room temperature in 4% formaldehyde, 0.1 M P0 4 buffer pH 7.5, and ⁇ nsed three times m PBS.
  • RNA-easy spin column Qiagen, Chatsworth, CA
  • the RT-PCR employed a two buffer thermostable Tth polymerase system (Promega, Madison, WI) according to manufacturer's instructions and lacL sequence p ⁇ mers from nucleotides 105 to 124 (forward) and 303 to 286 (reverse). Rnase and Dnase digestions prior to the RT-PCR were performed as previously desc ⁇ bed (van Gmkel, P., W. Hauswirth (1994) J. Biol. Chem. 269:4986-4992).
  • Example 1 Design of rAAV Vectors for Gene Transfer to Photoreceptors
  • a 472bp of the proximal murme rod opsm promoter (+86 to -385) was linked to a lacZ-SV40 polyA reporter gene and then inserted this into pTR.
  • the gene construct was packaged into
  • AAV virus particles concentrated, tested for contaminating Adenovirus and titered for recombmant AAV by an infectious center assay.
  • the ⁇ ght eyes of 30 C57B1/6J mice were injected sub-retmally with l ⁇ l of mOp-/ ⁇ cZ virus (10 7 m per ml). After two weeks, the right
  • test and left (control) eyes of 12 animals were removed, fixed and stained with X-gal.
  • Test retina in 6 of 12 injected eyes exhibited a focal blue region consistent with a subretmal bleb of the injected virus creating a localized retinal detachment. All control eyes showed no X-gal reaction. Reporter gene expression was examined in mice sacrificed at later periods and was detected at 10 weeks post-mjection suggesting persistent reporter transgene expression.
  • lacZ gene product was analyzed at higher resolution by preparing se ⁇ al 50 ⁇ m transverse sections from the entire whole mounts.
  • the blue X-gal reaction product is observed p ⁇ manly in the PR inner segments.
  • Most of the PRs were filled with X-gal in this region.
  • X-gal staining was slightly above control levels in the PR synaptic termini m the outer plexiform layer.
  • PR outer segments, RPE and other retinal cells in this region did not reveal X- gal staining above baseline levels observed m identically treated, unmjected or PBS-mjected control returns from the contralateral eye.
  • the 199bp amplification product diagnostic for lacZ RNA (nucleotides 105 to 303) can be seen when total RNA from a portion of a mouse retma sacrificed at 2 weeks post-mjection is amplified.
  • the amplification template was a cellular RNA because of its resistance to Dnase pretreatment and sensitivity to Rnase pretreatment.
  • the remaining RPE tissue was negative for this RT-PCR product. This demonstrates that the observed X-gal product was denved from ⁇ - galactosidase expression within PR cells and not denved from RPE expression.
  • a second reporter gene a synthetic version of the A victo ⁇ a green fluorescent gene (gfp) (Zolotukhin, S. M. Potter, W. Hauswirth, J. Guy, N. Muzyczka (1996) J Virol 70:4646-
  • GFP fluorescence typically extended over 10-20% of the retinal area m a radial pattern from the injection site. Immediately surrounding the point of infection, the transduction frequency, as judged by the intensity of GFP fluorescence, was very high, with a continuous positive signal. In transverse sections extending from the central retma to the pe ⁇ phery, beyond a region of apparently saturated GFP fluorescence, the percentage of transduced cells decreased radially with distance from the injection site. GFP-positive cells were easily identifiable as PRs by their specialized shape and location m the retma. Hence, only PR cells appeared to have been transduced, i.e., infected by the rAAV and expressing the gfp passenger gene.
  • Example 3 Opsm Promoter Confers Photoreceptor Cell Specificity
  • the PR-specific pattern of GFP expression was confirmed by laser confocal microscopy. GFP was not observed between the inner limiting membrane (vitreal face of the inner retma) and the outer plexiform layer (OPL) (junction of the inner retma with PR synaptic termini). This region contains all the non-PR retinal neuronal (bipolar, ho ⁇ zontal, amac ⁇ ne, and ganglion) and ghal (M ⁇ ller) cells. Virtually 100% of the PR inner segments, cell bodies, and synaptic terminals exhibited strong GFP fluorescence. In regions more peripheral to the injection site, the fraction of positive PRs was substantially reduced, consistent with the radial decline in fluorescence seen retinal whole mounts. It was established that all PR cell bodies contained
  • GFP signal by examining se ⁇ al optical sections (0.32 ⁇ m). Through-focus series demonstrated that occasional, dark regions in the ONL always contained a gfp-positive PR cell body in another plane of section. Therefore, all PRs, including both rods and cones, supported reporter gene expression. Outer segments demonstrated less fluorescence than other PR compartments, near the level of autofluorescence seen in control outer segments. No GFP signal was observed m the REP, choroid, or sclera.
  • GFP-positive PRs The area of GFP-positive PRs resulting from a typical injection from epifluorescence images of retinal whole mounts was established. GFP -positive areas were measured with NIH
  • Image software by segmenting the image into regions of GFP fluorescence and background on the basis of gray level. Area measurements were calibrated by imaging a 1000 ⁇ m reference scale on the film together with the whole mount.
  • the retinal area that contained 50% or more PR cells positive for GFP signal m whole mounts was measured. On average, the GFP-positive area covered -35% of the total retinal area of the rat retma.
  • the number of GFP -positive PRs resulting from a typical injection was estimated by examining se ⁇ al optical sections taken through the retma. Serial confocal images suggest 100% PR transduction m the region directly adjacent to the injection site, since we did not observe GFP-negative cell bodies within the outer nuclear layer m adjacent confocal optical sections. It is estimated that the whole rat retina contains 15.7 million PR cells. From these observations, a conservative estimate is that 2-3 million PRs were transduced by the gfp- containmg rAAV.
  • Example 5 Construction of Vectors and Expression in Target Cells rAAV- ⁇ bozyme constructs. Recombmant AAV constructs were based on the pTR-UF2 vector (Zolotukhm, S., M. Potter, W.W. Hauswirth et al. [1996] J Virol. 70:4646-4654). They resemble the vector used by Flannery et al. (Flannery, J.G., S. Zolotukhm, M.I. Vaquero et al [1997] Proc. Natl.
  • bovine promoter fragment contains three proximal promoter elements and the endogenous transc ⁇ ptional start site at its 3' end (DesJardm, L.E., W W. Hauswirth [1996] Inv Ophth. Vis. Sci. 37:154-165) and supports high efficiency, rat photoreceptor-specific expression in vivo.
  • ⁇ bozymes Active and inactive ⁇ bozymes were designed, tested and cloned. Each ⁇ bozyme gene was followed by an internally cleaving hairpm nbozyme derived from plasmid pHC (Althoffr, M., R. T ⁇ tz, A.A. Hampel [1992] Gene 122:85-90) resulting in ⁇ bozyme cassettes of 140-152 bp. Self cleavage at the internal cutting site m the primary nbozyme RNA leaves identical 3' ends on each mature nbozyme.
  • the ⁇ bozyme cassette was preceded by an intron derived from SV40 and followed by a polyadenylation signal in order to promote nuclear export of the nbozyme.
  • Recombmant AAV titers were determined using both an infectious center assay (Flannery, J.G., Zolotukhm, S. Vaquero et al. [1997] Proc. Natl. Acad. Sci. USA 94:6916-6921) and a DNAse resistant physical particle assay employing a quantitative, competitive PCR of the ne gene contained within all rAAV- ⁇ bozyme particles (Zolotukhm, S., M. Potter, W.W. Hauswirth et al. [1996]
  • Each of the four rAAV- ⁇ bozyme virus preparations contained 10 10 to 10" DNASE resistant particles per ml and 10 8 to 10 9 infectious center units per ml. Contaminating helper adenovirus and wild-type AAV, assayed by serial dilution cytopathic effect or infectious center assay respectively, were less than five order of magnitude lower than rAAV.
  • RNA retma were isolated without fixation and total RNA immediately extracted using the
  • RNeasy Minikit Qiagen, Santa Clanta, CA. RT-PCR was performed using the Pharmacia First-Strand cDNA synthesis kit employing ohgo dT as the primer. Wild-type and transgene opsm cDNAs were amplified using a three p ⁇ mer system desc ⁇ bed above. P ⁇ mers specific for ⁇ -actm cDNA (Timmers, A.M., B.R. Newton, W.W. Hauswirth [1993] Exp Eye Res 56:251- 265) were included in each reaction for internal standardization.
  • Ribozymes were designed to recognize and cleave the unique transc ⁇ pt produced by the P23H transgene.
  • the mutant target sequence "5 '-UCGGAGUCUACUUCG-3 '" (SEQ ID NO. 17) contains two differences from the wild-type mRNA (indicated in bold). The hairpm nbozyme (Hpl l) cleaved 3' to the first adenosine residue (underlined) and the hammerhead ⁇ bozyme (Hhl3) cleaved 3' to the central cytosme residue (underlined).
  • Control nbozymes (Hpl li and Hhl3 ⁇ , respectively) retained the targeting domains but contained fatal flaws in their catalytic domains.
  • the active hammerhead nbozyme (Hhl3) was able to cleave 20% of the P23H target within 10 mm. of incubation and by 5 hours greater than 80% was converted to the expected products.
  • both nbozymes exhibited kinetic constants (K,-, and k- at ) similar to those of naturally occurnng ⁇ bozymes.
  • the two active ribozymes produced negligible cleavage of the wild-type transcnpt even in the presence of high MgCl 2 concentrations.
  • Control ⁇ bozymes (Hpl li and Hhl3 ⁇ ) containing inactivating mutations in their catalytic domains were without measurable activity on any substrate Using total RNA denved from retinas of P23H rats on P62, both the hairpm and the hammerhead ⁇ bozymes were able to cleave the mRNA product of the mutant transgene selectively.
  • TgN(P23H)3 (abbreviated P23H-3), that has a retinal degeneration phenotype similar to patients with retmitis pigmentosa (Steinberg, R.H., J.G. Flannery, M.I. Naash et al. [1996] Inv. Ophth Vis. Sci 37:S698) was used.
  • mutated opsm transgene begins at about postnatal day (P) 5 in rats, leading to a gradual death of photoreceptor cells. These rats develop an apparently normal retma up to PI 5, although there are somewhat more pyknotic photoreceptor nuclei m the outer nuclear layer (ONL) than m non-transgemc control rats. Thereafter, death of photoreceptor cells is almost linear until about P60, resulting m loss of about 40% of the photoreceptors. After P60, the rate of cell loss decreases, until by one year the retinas have less than a single row of photoreceptor nuclei.
  • the rAAV-nbozyme vector was injected into the mterphotoreceptor space between the photoreceptors and the adjacent retinal pigment epithelium at P14 or P15. Rats were sacnficed and eyes examined at 3 time points between P60-P90. At these ages in unmjected control eyes of P23H-3 rats, the ONL thickness, which is an index of photoreceptor cells number, was reduced to about 60% of normal.
  • Ribozyme-mjected eyes showed a modest but significant decrease in the accumulation of transcnpt denved from the P23H transgene. Control eyes exhibited little vanation in the level of transgene opsm mRNA. Eyes injected with either active ⁇ bozyme uniformly exhibited lowered transgene mRNA levels relative to total opsm mRNA in the same eye. Retinas receiving the hairpm ⁇ bozyme Hpl 1 showed a 15.3 ⁇ 3.3% decrease m transgene expression, and those with the hammerhead nbozyme Hhl3 showed a decrease of 11.1+5.1% decrease
  • the upper bound denves from the DNAse resistant particle assay, indicating that 2 ⁇ l of the rAAV- ⁇ bozyme virus preparation contained 2 x 10 7 to 10 8 rAAV This is an upper bound because not all particles counted are expected to be infectious.
  • the lower bound for rAAV titer is generated by the infectious center assay, indicating 10 6 to 10 7 rAAV per ⁇ l.
  • rAAV retinal pigment epithelium
  • the initial volume of extracellular space approximately 0.5 ⁇ l, increases greatly with the 2 ⁇ l injection.
  • the fluid transport function of the RPE dehydrates this space, reapposmg the photoreceptors and RPE and concentrating the rAAV
  • the detachment of the photoreceptors from the RPE resolves withm several hours Du ⁇ ng the reattachment process, viral particles are spread laterally through the subretmal space.
  • RIS the unmjected control retinas had RIS that were about 90% of normal. Both the active and inactive ⁇ bozymes resulted m RIS lengths of 98% or greater of the normal length, and about 10- 15% longer than unmjected controls.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des produits et des traitements suscitant une expression satisfaisante et spécifique de protéines dans les cellules photorécepteurs de la rétine. Plus particulièrement, les produits de recombinaison sont constitués d'un vecteur viral associé aux adénovirus renfermant un promoteur d'opsine des bâtonnets ou des cônes rétiniens. Ces produits et traitement conviennent à des thérapies adaptées à des affections rétiniennes. Selon une réalisation, pour soigner la rétinite pigmentaire, on utilise des ribozymes qui dégradent l'ARNm mutant.
EP98922042A 1997-04-21 1998-04-21 Produits agissant contre des affections retiniennes et traitement correspondant Withdrawn EP0977880A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4449297P 1997-04-21 1997-04-21
US44492P 1997-04-21
US4614697P 1997-05-09 1997-05-09
US46146P 1997-05-09
PCT/US1998/008003 WO1998048027A2 (fr) 1997-04-21 1998-04-21 Produits agissant contre des affections retiniennes et traitement correspondant

Publications (1)

Publication Number Publication Date
EP0977880A2 true EP0977880A2 (fr) 2000-02-09

Family

ID=26721632

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98922042A Withdrawn EP0977880A2 (fr) 1997-04-21 1998-04-21 Produits agissant contre des affections retiniennes et traitement correspondant

Country Status (6)

Country Link
EP (1) EP0977880A2 (fr)
JP (1) JP2001527399A (fr)
AU (1) AU7467598A (fr)
BR (1) BR9809284A (fr)
CA (1) CA2287495A1 (fr)
WO (1) WO1998048027A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234999A1 (en) * 1996-04-02 2004-11-25 Farrar Gwenyth Jane Genetic suppression and replacement
US8551970B2 (en) 1996-04-02 2013-10-08 Optigen Patents Limited Genetic suppression and replacement
CA2287508A1 (fr) 1997-04-21 1998-10-29 The University Of Florida Substances et methodes de traitement de maladies retiniennes par les ribozymes
WO2000066780A2 (fr) 1999-04-30 2000-11-09 University Of Florida Ribozymes fournis par virus adeno-associes pour la decouverte de fonctions geniques
AU2001295193A1 (en) * 2000-05-01 2001-11-12 Novartis Ag Vectors for ocular transduction and use thereof for genetic therapy
EP1381276A4 (fr) 2001-04-13 2005-02-02 Univ Pennsylvania Traitement soignant ou retardant l'installation de la cecite
AU2007247929A1 (en) 2006-05-04 2007-11-15 Pennsylvania College Of Optometry Restoration of visual responses by In Vivo delivery of rhodopsin nucleic acids
EP2910637A1 (fr) 2008-05-20 2015-08-26 University of Florida Research Foundation, Inc. Vecteurs pour la délivrance de protéines photosensibles et procédés d'utilisation
DK2539015T3 (da) 2010-02-26 2016-04-04 Univ Cornell Nethindeprotese
GB2492719A (en) 2010-04-05 2013-01-09 Eos Neuroscience Inc Methods and compositions for decreasing chronic pain
US9453241B2 (en) 2010-05-04 2016-09-27 Wayne State University AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
BR112013004964A2 (pt) 2010-08-31 2017-05-23 Univ Cornell aparelho protético para recuperar ou melhorar a visão de um indivíduo em necessidade do mesmo
US9302103B1 (en) 2010-09-10 2016-04-05 Cornell University Neurological prosthesis
AU2012255735B2 (en) 2011-05-18 2017-05-25 The Regents Of The University Of California Compositions and methods for treating retinal diseases
WO2013029008A1 (fr) 2011-08-25 2013-02-28 Cornell University Codeur rétinien pour vision industrielle
AU2012327236B2 (en) 2011-10-28 2016-11-10 University Of Florida Research Foundation, Inc. Chimeric promoter for cone photoreceptor targeted gene therapy
EA201491643A1 (ru) 2012-03-05 2015-02-27 Уэйн Стейт Юниверсити Идентификация мутаций канал-опсина-2 (chop2) и способы применения
CN112842690B (zh) 2015-04-20 2023-10-17 康奈尔大学 具有维度数据缩减的机器视觉
CA3125294A1 (fr) * 2019-01-23 2020-07-30 University Of Florida Research Foundation, Incorporated Transduction et propagation laterale hautement efficaces dans la retine par un nouveau virus aav ameliore par conception rationnelle

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519299D0 (en) * 1995-09-21 1995-11-22 Farrar Gwyneth J Genetic strategy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9848027A2 *

Also Published As

Publication number Publication date
CA2287495A1 (fr) 1998-10-29
BR9809284A (pt) 2004-08-03
WO1998048027A2 (fr) 1998-10-29
JP2001527399A (ja) 2001-12-25
WO1998048027A3 (fr) 1999-03-25
AU7467598A (en) 1998-11-13
WO1998048027A9 (fr) 1999-04-29

Similar Documents

Publication Publication Date Title
EP0977880A2 (fr) Produits agissant contre des affections retiniennes et traitement correspondant
US10383922B2 (en) AAV-mediated gene therapy for RPGR X-linked retinal degeneration
US6225291B1 (en) Rod opsin mRNA-specific ribozyme compositions and methods for the treatment of retinal diseases
JP7095994B2 (ja) ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法
JP2022037158A (ja) 錐体細胞における増強された遺伝子発現のための組成物および方法
Bennett et al. Adenovirus-mediated delivery of rhodopsin-promoted bcl-2 results in a delay in photoreceptor cell death in the rd/rd mouse
US20110021605A1 (en) Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
JP7097398B2 (ja) ミオシリン（ｍｙｏｃ）緑内障を処置するためのアデノ随伴ウイルスベクター
JP2021507723A (ja) 視細胞における治療遺伝子の機能的発現を増強するための組成物および方法
WO2003093479A1 (fr) Systemes et methodes d'expression amelioree de raav permettant d'ameliorer la transduction de cellules neurales de mammiferes
US20040208847A1 (en) Method and vectors for selectively transducing retinal pigment epithelium cells
Auricchio et al. Adeno-associated viral vectors for retinal gene transfer and treatment of retinal diseases
Flannery et al. Ribozyme-mediated gene therapy for autosomal dominant retinal degeneration
US20040261141A1 (en) Animal model for therapy of diseases of the eye
Matsuki Development of gene therapy for achromatopsia due to CNGA3 mutations
EA046019B1 (ru) Композиции и способы лечения нарушений сетчатки
Wiley et al. ASSESSMENT OF AAV SEROTYPE TROPISM IN HUMAN RETINAL EXPLANTS.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991019

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19991019;LT PAYMENT 19991019;LV PAYMENT 19991019;MK PAYMENT 19991019;RO PAYMENT 19991019;SI PAYMENT 19991019

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20000216